Resource impact statement
No significant resource impact is anticipated
Entrectinib is recommended, within its marketing authorisation, as a further treatment option for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).
This is because the ROS1 gene fusion is rare, with around 40 people per year currently accessing an alternative treatment. Entrectinib is a further treatment option with no anticipated increase in the eligible population.
Entrectinib has a commercial arrangement (simple discount patient access scheme). This makes entrectinib available to the NHS with a discount. The size of the discount is commercial in confidence. For enquiries about the patient access scheme welwyn.rx_bdop@roche.com.
Entrectinib is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: